The bright side of psychoactive substances: cannabinoid-based drugs in motor diseases

Coccurello, R. and Bisogno, T. (2016) The bright side of psychoactive substances: cannabinoid-based drugs in motor diseases. Expert Review of Clinical Pharmacology, 9 (10). pp. 1351-1362. ISSN 1751-2433

Coccurello&Bisogno.pdf - Accepted Version

Download (877kB) | Preview
Official URL:


Introduction: psychoactive substances are associated with the idea of drugs with high addictive liability, affecting mental states, cognition, emotion and motor behavior. However these substances can modify synaptic transmission and help to disclose some mechanisms underlying alterations in brain processing and pathophysiology of motor disease. Hence, the “bright side” of e cannabinoid-based drugs must be thoroughly examined to be identified within the latter framework. Areas covered: we will analyze the preclinical and clinical evidence of cannabinoid-based drugs, discussing their therapeutic value in basal ganglia motor disorders such as Parkinson’s disease and Huntington disease. Expert commentary: despite the knowledge acquired in the last years, the therapeutic potential of cannabinoid-based drugs should be further tested by novel routes of investigation. This should be focused on the role of cannabinoid signaling system in mitochondrial function as well as on the physical and functional interaction with other key receptorial targets belonging to this network.

Item Type: Article
Uncontrolled Keywords: Parkinson’s disease; Huntington disease; endocannabinoid system; motor diseases; cannabinoid-based drugs; neuroprotection.
Subjects: 500 Scienze naturali e Matematica > 570 Scienze della vita; Biologia
Depositing User: PhD Roberto Coccurello
Date Deposited: 19 Dec 2016 14:02
Last Modified: 19 Dec 2016 14:02

Actions (login required)

View Item View Item